Vaccine development for Alzheimer's disease: a shot of good news.
Studies in transgenic mouse models of Alzheimer's disease suggest the potential for vaccine development for this disease. Specifically, inoculation with Abeta peptide reduces Abeta plaque formation. However, this vaccination strategy has raised safety concerns. Recent studies have reduced these concerns by demonstrating that long-term Abeta vaccination in transgenic mice does not produce detrimental behavioral effects and in fact appears to protect against age-related functional decline in spatial memory tasks.
Ingram
D K
DK
Behavioral Neuroscience Section, Laboratory of Neuroscience, Gerontology Research Center, National Institute on Aging, National Institutes of Health, 5600 Nathan Shock Lane Drive, Baltimore, MD 21224, USA. doni@vax.grc.nia.nih.gov
D000544:Alzheimer Disease / Q000628:therapy*; D016564:Amyloid beta-Protein Precursor / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D006801:Humans; D016233:Immunotherapy, Active; D007858:Learning / Q000187:drug effects* / Q000502:physiology; D051379:Mice; D008822:Mice, Transgenic
D016564:Amyloid beta-Protein Precursor